Invokana Linked to Diabetic Ketoacidosis (Ketosis)
FDA Investigates Type 2 Diabetes Medicines: Invokana, Invokamet
The dangerous drugs and products liability lawyers with The Cochran Firm – Dothan are reviewing potential claims of clients who have taken Invokana and have been diagnosed with diabetic ketoacidosis (ketosis) or kidney failure.
What is Invokana?
Invokana (canagliflozin) was the first drug of a new class of diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. These medications are approved by the Food and Drug Administration to lower blood sugar by causing the kidneys to remove sugar from the body through the urine. Other drugs in the class of SGLT2 inhibitors used to lower blood sugar in adults with type 2 diabetes which may produce the same side effects include:
- Invokana (canagliflozin)
- Invokamet (canaglifloizin / metformin)
- Jardiance (empagliflozin)
- Xigduo XR (dapagliflozin / metformin)
- Farxiga (dapagliflozin)
- Glyxambi (empagliflozin / linagliptin)
Side Effects and Risks of Invokana
In May 2015, the FDA issued a drug safety announcement that it was investigating reports that certain type 2 diabetes drugs caused a serious medical condition known as ketoacidosis. Also known as acidosis or diabetic ketoacidosis (DKA), this condition causes the body to produce excessive levels of blood acids, or ketones, which can lead to serious conditions including diabetic coma, brain swelling or death.
Ketoacidosis and kidney failure are the most serious complications associated with the use of Invokana. Diabetic ketoacidosis is a serious but treatable medical condition where high levels of ketones are produced in the body and build up in the blood and urine.
Diabetic Ketoacidosis Symptoms
Approved by the FDA in March 2013, Invokana was developed by Mitsubishi Tanabe Pharma, and is marketed Johnson & Johnson’s Janssen Pharmaceuticals, Inc. The FDA identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014.
The FDA has also warned that patients who are taking Invokana (or any class of SGLT2 inhibitors) should not stop or change their diabetes medicines without talking to your physician. Patients who experience symptoms of ketoacidosis should seek immediate medical attention. These symptoms include:
- Difficulty breathing
- Abdominal pain
- Unusual fatigue or sleepiness
Invokana Lawsuit Lawyer
Our trial lawyers have extensive experience and resources in defective drugs and products liability cases. They have aggressively represented numerous clients who have suffered serious side effects or the death of a loved one from the use of defective medical devices and dangerous or defective drugs. If you or someone you know have been diagnosed with diabetic ketoacidosis while taking a diabetes medication known as a SGLT2 inhibitor, call the personal injury lawyers at The Cochran Firm in Dothan, Alabama.
For a free consultation and review of your case, call our office to talk with one of our Invokana lawyers:
(334) 673-1555 or 1-800-The Firm.